A groundbreaking development in the field of multiple sclerosis (MS) treatment has emerged with the administration of an “off-the-shelf” CAR T-cell therapy known as azercabtagene zapreleucel (azer-cel) to a patient with MS. This innovative approach involves utilizing genetically engineered T-cells from healthy donors to target the immune cells responsible for inflammation and damage in MS. The experimental treatment, administered as part of a U.S.-based Phase 1 clinical trial at Nebraska Medicine’s Fred & Pamela Buffett Cancer Center, aims to assess the safety and efficacy of this novel donor-derived CAR T-cell therapy in individuals with progressive forms of MS.
CAR T-cell therapy represents a promising avenue in immunotherapy, involving the modification of T-cells to express chimeric antigen receptors (CARs) that enable them to selectively target specific proteins. While traditional CAR T-cell therapies utilize a patient’s own T-cells, the allogeneic approach employed in azerc-cel allows for the development of an “off-the-shelf” treatment that can be standardized and used across multiple patients. By targeting the CD19 protein present on B-cells, which play a significant role in driving MS, this therapy aims to mitigate disease symptoms by reducing the levels of these immune cells.
The utilization of allogeneic CAR T-cell therapy to target immune cells associated with inflammation and damage in the central nervous system represents a pioneering step in MS treatment. While this approach has previously been explored in B-cell-related blood cancers, ongoing clinical trials are now investigating its potential in B-cell mediated autoimmune disorders. The current trial, conducted at multiple sites in the U.S., involves a treatment regimen consisting of chemotherapy to eliminate faulty immune cells followed by a single infusion of azer-cel, with patients being closely monitored over an extended period to evaluate treatment safety, pharmacological properties, and its impact on disease progression.
The inaugural recipient of this cutting-edge therapy for MS, Jan Janisch-Hanzlik, shared her experience of participating in the trial after experiencing rapid disease progression. Following the infusion of azer-cel, Janisch-Hanzlik and other participants will undergo thorough assessments to gauge the therapy’s effectiveness in slowing disability progression, reducing lesions, and preventing brain shrinkage. This personalized approach to MS treatment holds significant promise not only for individual patients like Janisch-Hanzlik but also for the broader MS community, offering new possibilities for improving outcomes and quality of life.
Key Takeaways:
– Off-the-shelf CAR T-cell therapy utilizing donor-derived T-cells shows promise in targeting immune cells driving inflammation in MS.
– Allogeneic CAR T-cell therapy represents a novel therapeutic approach for autoimmune disorders like MS, with ongoing trials investigating its efficacy.
– Initial results of the Phase 1 clinical trial suggest the potential of azer-cel in slowing disability progression and reducing disease activity in MS patients.
Tags: clinical trials, immunotherapy
Read more on multiplesclerosisnewstoday.com